In remote ischemic conditioning (RIC), brief, reversible episodes of ischemia with reperfusion in one vascular bed, tissue, or organ confer a global protective phenotype and render remote tissues and organs resistant to ischemia/reperfusion injury. The peripheral stimulus can be chemical, mechanical, or electrical and involves activation of peripheral sensory nerves. The signal transfer to the heart or other organs is through neuronal and humoral communications. Protection can be transferred, even across species, with plasma-derived dialysate and involves nitric oxide, stromal derived factor-1a, 
There was no difference in the magnitude of the infarct-sparing effect seen in donor-and acceptorpre-conditioned groups, implying that the efficacy of cardioprotection triggered by RIC was comparable to that achieved by conventional ischemic preconditioning (5) . This general strategy, involving transfer of effluent or perfusate, has been refined to include collection of serum following brief preconditioning ischemia applied in vivo and its administration to either isolated hearts or cultured cells subjected to a sustained ischemic or hypoxic insult (9) (10) (11) . This strategy also provided evidence of crossspecies protection by RIC, including treatment of isolated buffer-perfused rabbit hearts with human serum (9, 11) .
It could be argued that intracardiac RIC or cardioprotection achieved by transfer of perfusate between hearts is a laboratory curiosity providing mechanistic insight, but of limited translational relevance. Accordingly, the observation of interorgan RIC was a pivotal pre-clinical advance (12) . Initial evidence revealed that brief episodes of ischemia/ reperfusion in kidney and mesentery rendered the heart resistant to infarction (12) (13) (14) (15) . Moreover, a number of studies documented RIC-induced attenuation of ischemia/reperfusion injury in brain, lungs, liver, kidney, intestine, skin, and other tissues (reviewed in Candilio et al. [16] ). However, the first reported seminal extension of interorgan RIC in a clinically-relevant, large-animal (swine) model (17) , which demonstrated that brief episodes of peripheral limb ischemia, achieved by simple tourniquet occlusion of one hindlimb, was sufficient to evoke a profound reduction in myocardial infarct size, accelerated subsequent implementation of phase II trials aimed at establishing efficacy in patients (17) . T e m p o r a l v a r i a n t s : r e m o t e p r e -, p e r -, a n d p o s tc o n d i t i o n i n g . In all studies discussed thus far, the remote conditioning stimulus was administered prophylactically in the w30-to 40-min period before the onset of sustained myocardial ischemia. However, pre-treatment is not a requirement for RIC-induced cardioprotection: reduction of infarct size has also been described with concurrent application of the remote ischemic stimulus during sustained coronary occlusion (remote ischemic per-conditioning)
or at the time of reperfusion (remote ischemic postconditioning) (24,25).
The first documentation of infarct size reduction with remote per-conditioning utilized brief renal ischemia/reperfusion as the trigger, applied during and subsequently corroborated in other models, including rabbit and rat (8, 30 Langendorff bioassays have also been used to test for the presence of circulating cardioprotective factors in human RIC. Depending on whether peripheral neuropathy was present, dialyzed plasma from diabetic patients subjected to RIC had differential responses, confirming interaction between the neural and humoral components of remote conditioning (11) . Whereas plasma from diabetic patients without neuropathy was highly cardioprotective in naïve acceptor rabbit hearts, patients with peripheral neuropathy failed to provide cardioprotective plasma.
Most recently, RIPC had no effect on exercise performance in heart failure patients (50). However, in the isolated mouse heart bioassay, plasma from heart failure patients was cardioprotective at baseline, Although the exosome fraction was not tested for
Remote Ischemic Conditioning cardioprotective activity in that study, effluent from a pre-conditioned heart was able to protect a second heart unless microvesicles and exosomes were removed, demonstrating that protection depends upon their presence (62) . In summary, more work is required to identify whether microRNA-144, other microRNAs, chemokines, and perhaps undiscovered circulating factors may act either alternately or in concert as the humoral signal transferring protection to the heart. Nitric oxide, stromal-derived factor-1a, Early studies using pharmacological antagonists identified the involvement of adenosine (13, 26) , bradykinin (14, 19, 65) , opioids (37,66,67), epoxyeicosatrienoic acids (19) , reactive oxygen species (66) , and adenosine triphosphate (ATP)-dependent potassium channels (13, 27 ), but could not dissect whether these molecules/mechanisms were involved in signal generation within the remote organ, transfer of the signal to the heart, cardioprotective signaling in the heart, or any combination of these steps. To attribute signaling to the heart, the signal must be demonstrated to localize in the myocardium or an antagonist must be given in the transfer fluid obtained after a RIC protocol in a donor organism, then administered to an isolated recipient and target heart. However, EFFECTS OF RIC ON THE HEART: AMI. Although the incidence of AMI is declining in the Western World (136, 137) , ischemic heart disease is still the leading cause of death worldwide (138) . Improvements in treatment have changed the epidemiology after AMI, with markedly improved 30-day survival, but have less favorably influenced long-term survival (136, 139) . Consistent with this, due to remodeling and heart failure (140), nonfatal ischemic heart disease has increased more than ischemic heart disease deaths since 1990 (138) . The declining incidence of heart failure after AMI has not reached the magnitude that we might have expected from clinical trial data (139) and the prevalence is increasing (138) .
Consequently, one of the potentially most important applications of RIC may be in patients with AMI (28,141-147) ( Table 3) . The first proof-of-concept study demonstrating that RIC can increase myocardial salvage investigated 333 patients undergoing primary PCI for STEMI, of whom 132 had available imaging data (28). Tables 1 and 2 . An emerging concept, known as chronic conditioning, is the daily use of RIC for a period of weeks.
In rats, RIC administration daily for the first 28 days after myocardial infarction had a dose-dependent effect on cardiac remodeling, heart failure, and even death rate in the absence of a significant reduction of infarct size (163) . This effect demonstrates benefits beyond modification of acute ischemic effects. However, in a recent pilot study, this did not immediately translate into improved exercise capacity in heart failure patients (50).
CONFOUNDING FACTORS IN RIC
No recognized effective therapeutic intervention for protecting the myocardium against the detrimental effects of ischemia-reperfusion injury presently ex- With late presentation, the infarct will have been completed, and the patient will derive little benefit from either intervention or an adjunct to reperfusion. Early presentation and revascularization will lead to small myocardial infarcts, and this patient will have little advantage from adjunctive therapy.
There is a "sweet spot," probably between 3 and 8 h from time of symptom onset to time of reperfusion,
for adjunctive therapies to demonstrate maximal benefit.
COMORBIDITIES AND COMEDICATIONS. In preclinical studies, age (172) and comorbid diseases (126) , such as hyperlipidemia, diabetes, and hypertension, which require a more robust conditioning signal, raise the threshold for protection. This raised cardioprotective threshold reflects fundamental molecular alterations within the heart, affecting both sensitivity to ischemia/reperfusion injury and response to a particular cardioprotective strategy (126, (172) (173) (174) . Unfortunately, most experimental models use healthy young animals, free of any comorbidities (175) . Experimental studies using human atrial muscle from patients undergoing CABG, from aged and diabetic patients and patients with heart failure (176-178) confirmed the effect of comorbidity on the conditioning threshold and demonstrated resistance to various conditioning strategies.
Pharmacological therapy also impacts cardio- Taking these confounders into consideration in the design of any clinical study investigating RIC is hugely important; we must either design a study that does not use these agents (which may be impractical)
or ensure that it is adequately powered and properly randomized.
EFFECTS OF RIC ON THE BLOOD AND VASCULATURE
Platelet activation is both a consequence and a driver of ischemia/reperfusion injury. Local ischemic preconditioning attenuates platelet activation and aggregation (182) . In humans, marked systemic platelet elderly hypertensive subjects benefitted more from RIC, whereas basal levels of flow-mediated dilation were significantly greater in the younger population (194) . RIC in healthy young subjects, repeated daily for 7 days (195) , was associated with progressively improved flow-mediated dilation and cutaneous vascular conductance (as a measure of microcirculatory function), which was sustained at 8 days after the cessation of RIC. In a subsequent study (196) 
